Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.58 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.58 |
| ▸ | CHAT | P28329 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL31621363 | 0.97 | SLC6A4 (0.90) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Iodide SCHEMBL31621372 | 0.97 | SLC6A4 (0.90) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| SCHEMBL37321 | 0.97 | SLC22A2 (1.00) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| SCHEMBL8827505 | 0.97 | SLC22A2 (1.00) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Hydrochloric Acid SCHEMBL30020113 | 0.94 | SLC22A2 (0.94) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Hydrochloric Acid SCHEMBL163494 | 0.94 | SLC22A2 (0.94) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| SCHEMBL7577787 | 0.90 | SLC22A2 (0.85) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Paraquat SCHEMBL11281521 | 0.88 | SLC6A4 (0.72) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Paraquat SCHEMBL4895671 | 0.85 | SLC6A4 (0.77) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 | |
| Paraquat SCHEMBL21652 | 0.85 | SLC6A4 (0.77) | SLC6A4SLC22A2SLC22A1SLC22A3PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | COGMOTIV FLEXCO (AT) | 2026-04-28 | — | — | US | disclosed |
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-01-29 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250241878-A1 | TYROSINE AND RESVERATROL DERIVATIVES AS NOVEL MODULATORS OF CELLULAR SERINE ADP-RIBOSYLATION | UNIVERSITY OF SOUTH CAROLINA | 2025-07-31 | — | — | US | disclosed |
| US-12351595-B2 | Composition comprising O-cyclic phytosphingosine-1-phosphate for preventing or treating Parkinson's disease | AXCESO BIOPHARMA CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| CN-120136777-A | C4-aryl pyridine iodized salt organic room-temperature phosphorescent material, and preparation method and application thereof | 天津师范大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-114269745-B | Heteroaryl substituted pyrazolopyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20250090571-A1 | CARD9 ATTENUATES AB PATHOLOGY AND MODIFIES MICROGLIAL RESPONSES IN AN ALZHEIMER’S DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2025-03-20 | — | — | US | disclosed |
| CN-119564831-A | Application of beta-Syn protein in preparation of parkinsonism medicament | 河南大学 | 2025-03-07 | — | — | CN | disclosed |
| US-20250032557-A1 | Novel Strain Having Antagonism Against Proteus Mirabilis and Excellent Effect on Neurodegenerative Disease, and use Thereof | METACEN THERAPEUTICS CO., LTD (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-0832151-A2 | RESPONSIVE POLYMER NETWORKS AND METHODS OF THEIR USE | Gel Sciences, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5674521-A | DRUG DELIVERY SYSTEM COMPRISING POLYMER GEL NETWORK INCLUDING BIOLOGICALLY ACTIVE SOLUTE, SALT, LOADING POLYMER; REDUCED LOSS OF ACTIVITY | UNIVERSITY OF CINCINNATI (US) | 1997-10-07 | — | — | US | disclosed |
| US-5603955-A | GEL NETWORK; PROTECTIVE POLYMER; PROTECTANT SALT | UNIVERSITY OF CINCINNATI (US) | 1997-02-18 | — | — | US | disclosed |
| WO-1997000275-A2 | RESPONSIVE POLYMER NETWORKS AND METHODS OF THEIR USE | GEL SCIENCES, INC. (US) | 1997-01-03 | — | — | WO | disclosed |
| WO-1996002276-A9 | NOVEL POLYMER GEL NETWORKS AND METHODS OF USE | — | 1996-02-29 | — | — | WO | disclosed |
| WO-1996002239-A2 | ENHANCED LOADING OF SOLUTES INTO POLYMER GELS AND METHODS OF USE | UNIVERSITY OF CINCINNATI (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002276-A2 | NOVEL POLYMER GEL NETWORKS AND METHODS OF USE | GEL SCIENCES, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1993023012-A1 | LIQUID-CONTAINING DRUG DELIVERY SYSTEM | ENDOCON, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | SNCA, PARK7, LRRK2 | SLC6A4 1194/4885SLC22A2 4280/4885SLC22A1 4320/4885 |
| US-12351595-B2 | Composition comprising O-cyclic phytosphingosine-1-phosphate for preventing or treating Parkinson's disease | PYGB, DBH, SNCA | SLC6A4 817/4885SLC22A2 1689/4885SLC22A1 1316/4885 |
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | CHAT, PNMT, CHRM5 | SLC6A4 105/4885SLC22A2 3345/4885SLC22A1 2859/4885 |
| US-20250090571-A1 | CARD9 ATTENUATES AB PATHOLOGY AND MODIFIES MICROGLIAL RESPONSES IN AN ALZHEIMER’S DISEASE | CARD19, TLR9, CD209 | SLC6A4 3028/4885SLC22A2 3142/4885SLC22A1 3169/4885 |
| US-20250241878-A1 | TYROSINE AND RESVERATROL DERIVATIVES AS NOVEL MODULATORS OF CELLULAR SERINE ADP-RIBOSYLATION | PARP10, PARP11, RBBP9 | SLC6A4 3378/4885SLC22A2 4736/4885SLC22A1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.